Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir

(2018) Max Lataillade et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Impact of natural polymorphisms of HIV-1 non-group M on genotypic susceptibility to the attachment inhibitor fostemsavir

(2018) Elodie Alessandri-Gradt et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fostemsavir

(2018) Pedro Cahn et al.   Current Opinion in HIV and AIDS

Inhibitors of HIV-1 Attachment: The Discovery and Development of Temsavir and its Prodrug Fostemsavir

(2017) Nicholas A. Meanwell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529

(2017) Marie Pancera et al.   Nature Chemical Biology

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial

(2017) David Easterhoff et al.   PLoS Pathogens

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529

(2016) Ishani Landry et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

STRUM: structure-based prediction of protein stability changes upon single-point mutation

(2016) Lijun Quan et al.   BIOINFORMATICS

Current status and prospects of HIV treatment

(2016) Tomas Cihlar et al.   Current Opinion in Virology

The V1 region of gp120 is preferentially selected during SIV/HIV transmission and is indispensable for envelope function and virus infection

(2016) Yanpeng Li et al.   VIROLOGICA SINICA

The I-TASSER Suite: protein structure and function prediction

(2015) Jianyi Yang et al.   NATURE METHODS

BMS-663068, a safe and effective HIV-1 attachment inhibitor

(2015) Ester Ballana et al.   Lancet HIV

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

(2015) Jacob P Lalezari et al.   Lancet HIV

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes

(2014) D. B. Fofana et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry

(2014) Alon Herschhorn et al.   Nature Chemical Biology

Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action

(2014) David R. Langley et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors

(2013) Zhufang Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068

(2013) Neelanjana Ray et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B

(2013) C. Soulie et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068

(2013) N. Zhou et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0

(2013) Koichiro Tamura et al.   MOLECULAR BIOLOGY AND EVOLUTION

In VitroAntiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068

(2012) Beata Nowicka-Sans et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prevalence of subtype-related polymorphisms associated with in vitro resistance to attachment inhibitor BMS-626529 in HIV-1 'non-B'-infected patients

(2012) C. Charpentier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The Development of CD4 Binding Site Antibodies during HIV-1 Infection

(2012) R. M. Lynch et al.   JOURNAL OF VIROLOGY

Solution Structure, Conformational Dynamics, and CD4-Induced Activation in Full-Length, Glycosylated, Monomeric HIV gp120

(2012) Miklos Guttman et al.   JOURNAL OF VIROLOGY

European guidelines on the clinical management of HIV-1 tropism testing

(2011) LPR Vandekerckhove et al.   LANCET INFECTIOUS DISEASES

Specific Enfuvirtide‐Associated Mutational Pathways in HIV‐1 Gp41 Are Significantly Correlated With an Increase in CD4+Cell Count, Despite Virological Failure

(2008) Valentina Svicher et al.   JOURNAL OF INFECTIOUS DISEASES